Connect with us

Technology

Draper to Develop an Advanced, Multi-Organ, Microphysiological System Architecture

Published

on

Draper’s ETHOS program will create a scalable microphysiological system (MPS) architecture consisting of interacting advanced immune-competent micro-organ (liver, lung, kidney) models, which will be used to predict disease/injury response in the body and medical countermeasure response.

CAMBRIDGE, Mass., Nov. 21, 2024 /PRNewswire-PRWeb/ — The field of microphysiological systems has continued to evolve during the past 20 years, doing so in response to the tremendous challenges facing pharmaceutical development and national biodefense initiatives. This includes the high cost, lack of availability and limited human clinical relevance of animal models.

Draper looks forward to advancing these MPS-based capabilities for DTRA and their U.S. government partners in order to protect the warfighter against high-priority threats and accelerate our response to future threats.

Draper is responding to these national security challenges and announces the $34.1 million award of the Evaluation of Treatments using High-throughput Multi-Organ Systems (ETHOS) program.

The Defense Threat Reduction Agency (DTRA), Joint Science and Technology Office (JSTO), Vaccines/Therapeutics Division (CBM) is the government sponsor for this program.

DTRA’s Research and Development Directorate provides science, technology and capability development investments that maintain the U.S. military’s technological superiority in countering weapons of mass destruction and emerging threats, mitigate the risks of technical surprise and respond to the warfighters’ urgent technical requirements. (Sources: https://www.dtra.mil/About/Mission/Research-and-Development/, https://www.dtra.mil/Portals/125/Documents/CB/DTRA-JSTO_E-book_PDF.pdf)

The overall objectives of the ETHOS program are to create a scalable microphysiological system architecture that consists of interacting immune-competent micro-organ (lung, liver, kidney) models to predict the body’s disease response and test medical countermeasure (MCM) responses.

Draper’s advanced models will include parenchymal, vascular and innate immune components to capture a broad range of biological responses. The technical approach will be to create a new multi-organ platform to understand disease progression of high-priority BSL-3 agents and determine the safety and efficacy of MCM treatments.

“Draper looks forward to advancing these MPS-based capabilities for DTRA and their U.S. government partners in order to protect the warfighter against high-priority threats and accelerate our response to future threats,” said Roger Odegard, the Draper ETHOS program manager.

DTRA has recognized that significant research and development in the MPS technology area will improve the state-of-the-art capability to analyze the pathogenesis of disease and injuries that result from exposure to high-priority pathogens and toxins.

Additionally, next-generation MPS technologies and systems will be critical in the evaluation of efficacious and safe medical countermeasures (MCM) to combat these threats and allow the military to be equipped to meet its mission. This will include investigating and characterizing the mechanisms of infection/inflammation/tissue damage across relevant population demographics (e.g., military age, sex, co-morbidities and previous exposure) and under varying conditions (e.g., exposure levels, drug doses and time scales) for a variety of threats. These technology innovations represent a state-of-the-art tool for pharmaceutical solutions that has the potential to significantly accelerate the process of evaluating effective and safe MCMs for emerging, naturally or engineered threats.

This project has been funded in whole or in part with federal funds from the Department of Defense (DoD); The Defense Threat Reduction Agency (DTRA); Joint Science and Technology Office (JSTO), Vaccines/Therapeutics Division (CBM) through the Medical CBRN Defense Consortium (MCDC) Agreement No. MCDC2201-003.

Draper

Draper is an independent, nonprofit research and development company headquartered in Cambridge, Mass. with campuses located across the United States. The 2,300 employees of Draper tackle important national challenges with a promise of delivering successful and usable solutions. From military defense and space exploration to biotechnology, lives often depend on the solutions we provide. Our multidisciplinary teams of engineers and scientists work in a collaborative environment that inspires the cross fertilization of ideas necessary for true innovation. For more information about Draper, visit www.draper.com.

Media Contact

Scott Deitz, Draper, 1 336-908-7759, scott@sevenletter.com, Draper.com

View original content to download multimedia:https://www.prweb.com/releases/draper-to-develop-an-advanced-multi-organ-microphysiological-system-architecture-302313153.html

SOURCE Draper

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

INTOUCH INSIGHT ANNOUNCES Q3 2024 FINANCIAL RESULTS

Published

on

By

OTTAWA, ON, Nov. 21, 2024 /CNW/ – Intouch Insight Ltd, (“Intouch” or “the Company”) (TSXV: INX) (OTCQX: INXSF) a leader in customer experience measurement solutions, today announced financial results for the quarter ended September 30, 2024.

Key highlights for Q3 2024

Revenue increased 18% to $6,656,664 compared to $5,634,594 in Q3 2023.Recurring services revenue increased 23% to $5,761,966 from $4,678,154 the prior year Q3.Gross margin increased to 48.2% from 41.7% in Q2 2024 due to the shift in product mix.SaaS revenues grew 9% organically.Operating expenses have grown 7% compared to prior year’s Q3 as acquisition integration efforts continue.Adjusted EBITDA remained positive increasing to $575,889 compared to $296,515 in Q2, 2024 and $509,762 in prior year Q3.

“Our financials illustrate that Intouch is a growing, profitable and financially self-sufficient business.  Sales and marketing efforts are building on our thought leadership and improving brand recognition, particularly in the key target market segments of Quick Serve Restaurants and Petro Convenience, as evidenced by recent mainstage speaking invitations for four industry events,” said Cameron Watt, President & Chief Executive Officer of the Company.

“This year will mark the second year in a row with revenues over $25 Million and we expect growth to continue well beyond this level into the future,” said Watt.

Consolidated Statements of Operations

Q3 2024

Q3 2023

Revenue

$    6,656,664

$    5,634,594

Cost of services

3,445,180

2,719,682

Gross margin

3,211,484

2,914,912

Total operating expenses

2,844,721

2,656,381

Income from operating activities

366,763

258,531

Non-operating (expenses) income 

87,297

(83,076)

Income tax recovery (expense)

Net income (loss)

$       454,060

$       175,455

About Intouch Insight

Intouch Insight offers a complete portfolio of customer experience management (CEM) products and services that help global brands delight their customers, strengthen brand reputation and improve financial performance. Intouch helps clients collect and centralize data from multiple customer touch points, gives them actionable, real-time insights, and provides them with the tools to continuously improve customer experience. Founded in 1992, Intouch is trusted by over 300 of North America’s most-loved brands for their customer experience management, customer survey, mystery shopping, mobile forms, operational and compliance audits, geolocation data capture and event marketing automation solutions. For more information, visit intouchinsight.com.

Certain statements included in this news release contain forward looking statements that are made of the date hereof, which by their nature are necessarily subject to risks and uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Such statements reflect the Company’s current views with respect to future events, including the acquisition, future revenues and references to the Company’s expansion and growth of the business and operations, and are based on information currently available to the Company and on hypotheses which it considers to be reasonable; however, management warns the reader that hypotheses relative to future events which are beyond the control of management could prove to be false, given that they are subject to certain risks and uncertainties. Please refer to the risks set forth in the Company’s most recent annual MD&A and the Company’s continuous disclosure documents that can be found on SEDAR at www.sedar.com.   The Company does not intend, and disclaims any obligation, except as required by law, to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Intouch Insight Ltd.

Continue Reading

Technology

Beacon Healthcare Systems Expands Leadership Team with Addition of Ayman Mohamed as Chief Technology Officer

Published

on

By

HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ — Beacon Healthcare Systems, is pleased to announce the appointment of Ayman Mohamed as its new Chief Technology Officer, effective November 18, signaling a new direction in innovation and technology leadership. With over 20 years of senior leadership, strategic, and operational product management experience, Ayman brings a wealth of knowledge and expertise to the role.

Beacon Healthcare Systems Expands Leadership Team with Addition of Ayman Mohamed as Chief Technology Officer

Ayman Mohamed is a seasoned technology leader with a proven track record of launching innovative products in new and existing markets, generating significant revenue streams, and creating profitable enterprises. His passion for building high-quality products and commitment to servant leadership have earned him a reputation for building trust and fostering collaborative, high-performing teams.

Throughout his career, Ayman has demonstrated a deep understanding of software architecture and broad hands-on technical skills. He has successfully helped organizations succeed, with experience spanning startups and larger companies in the San Francisco Bay and Washington DC metro areas. In his new role at Beacon Healthcare Systems, Ayman will lead engineering and delivery teams, develop a product roadmap, and lead technology development, testing, and implementation efforts.

“We are thrilled to have Ayman join Beacon Healthcare Systems at this pivotal time. Our vision is to harness cutting-edge technologies to enhance our products, implementations, and continue to give our clients the level of quality they expect,” said Todd Petersen, CEO.

Ayman Mohamed’s previous roles include leadership positions at Amazon Web Services, American Well, Avizia, Intersections Inc, Zumetrics, Moasis Global, and Ultra Zoom Technologies. His strategic and operational skills, combined with his ability to thrive in dynamic environments and his bias for action, make him an invaluable asset to Beacon Healthcare Systems.

About Beacon Healthcare Systems. Beacon Healthcare Systems streamlines the business of healthcare through reliable innovative SaaS technology delivered by industry experts. With a focus on appeals and grievances, compliance, and analytics, Beacon HCS is the first place health plans turn when looking for a trusted, experienced partner that can help them reduce costs, grow revenue, and achieve their strategic goals. Founded in 2011, Beacon HCS is a privately held California-based company. Visit our website at www.beaconhcs.com

Media Contact: 9048744189 | Dkroog@beacon@beaconhcs.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/beacon-healthcare-systems-expands-leadership-team-with-addition-of-ayman-mohamed-as-chief-technology-officer-302313686.html

SOURCE Beacon Healthcare Systems

Continue Reading

Technology

NASA Awards Test Operations Contract

Published

on

By

WASHINGTON, Nov. 21, 2024 /PRNewswire/ — NASA has selected Sierra Lobo, Inc. of Fremont, Ohio, to provide for test operations, test support, and technical system maintenance activities at NASA’s Stennis Space Center near Bay St. Louis, Mississippi.

The NASA Stennis Test Operations Contract is fixed-price, level-of-effort contract that has a value of approximately $47 million. The performance period begins July 1, 2025, and extends three years, with a one-year base period and two one-year option periods.

The contract will provide test operations support for customers in the NASA Stennis test complex. It also will cover the operation and technical systems maintenance of the high-pressure industrial water, high-pressure gas, and cryogenic propellant storage support areas, as well as providing welding, fabrication, machining, and component processing capabilities.

NASA Stennis is the nation’s largest propulsion test site, with infrastructure to support projects ranging from component and subscale testing to large engine hot fires. Researchers from NASA, other government agencies, and private industry utilize NASA Stennis test facilities for technology and propulsion research and developmental projects.

For information about NASA and other agency programs, visit:

https://www.nasa.gov

View original content to download multimedia:https://www.prnewswire.com/news-releases/nasa-awards-test-operations-contract-302313691.html

SOURCE NASA

Continue Reading

Trending